“As innovation-led disruption fuels unprecedented levels of M&A activity for clients across all of Goodwin’s industries of focus, our antitrust team continues to play an essential role in ensuring our clients’ deals get the government approvals needed to move forward smoothly,” said Joanne Gray, chair of Goodwin’s litigation department. “With regulatory enforcement of the technology, life science, private equity, and other industries in sharp focus, Andy’s extensive experience across antitrust risks and opportunities will be invaluable to our clients’ success.”
Lacy has extensive experience advising clients on transaction-related antitrust risk, negotiating terms of agreements, and determining the applicability of merger clearance filing requirements in both U.S. and foreign jurisdictions. He represents clients before the FTC, DOJ, and state regulators in connection with informal inquiries, Second Requests, conduct investigations, and third-party subpoenas. Lacy has represented clients in merger challenges, class actions, and other private antitrust litigation matters. He also provides guidance on antitrust issues related to diligence and pre-closing conduct procedures, internal compliance programs, hiring and non-compete agreements, vendor agreements, and competitor collaborations. He is recognized by The Legal 500 U.S. and as a “Litigation Star” by Benchmark Litigation.
“The intersection of Goodwin’s market-leading M&A practice with its specialization in the technology, life sciences, and private equity sectors puts the firm at the forefront of the global economy,” said Lacy. “I’m thrilled to join such a skilled and collaborative team serving the innovators and investors who are driving deal-making and capitalizing on a new wave of opportunities.”
Over the past year, Goodwin has ranked at the top of the global M&A league tables. Refinitiv named Goodwin the number one legal advisor (by deal count) for global M&A in 2020. Mergermarket’s Deal Drivers FY 20 reports named Goodwin the number one firm (by deal count) for Pharma, Medical, and Biotech M&A in North America; the number two firm (by value) for Pharma, Medical, and Biotech M&A in Europe, the Middle East, and Africa; and the number three firm (by deal count) for Tech, Media, and Telecoms M&A in North America.
Goodwin’s Antitrust and Competition lawyers have advised clients — from the largest Fortune 500 companies to emerging growth companies — on more than 2,500 transactions before U.S. and international antitrust agencies. The team has successfully defended hundreds of matters through the Second Request process and other intensive government investigations.